



Important Note to investors in Short-Term Investments Company (Global Series) PLC

13 July 2017

Dear client,

Please note that following the provisions of Regulation (EU) 2015/2365 of the European Parliament and of the Council of 25 November 2015 on transparency of securities financing transactions and of reuse and amending Regulation (EU) No. 648/2012 ("SFTR"), the prospectus of the umbrella fund Short-Term Investments Company (Global Series) Plc ("STIC") is currently being amended and in the process of being reviewed by the Central Bank of Ireland ("CBI").

In compliance with the requirements of SFTR we would like to confirm that the sub-funds of STIC (the "Funds or each of them a "Fund") may invest in or use reverse repurchase agreements but will not invest in other Securities Financing Transactions ("SFTs") such as (i) repurchase agreements (ii) securities or commodities lending and securities or commodities borrowing; (iii) buy-sell back transaction or sell-buy transaction; or (iv) margin lending transactions or Total Return Swaps (TRS) within the meaning of the SFTR.

Please note the following disclosures in compliance with SFTR requirements:

1. Reverse repurchase agreements may be entered into for efficient portfolio management purposes.
2. Under a reverse repurchase agreement, a Fund acquires securities from a seller (for example, a bank or securities dealer) who agrees, at the time of sale, to repurchase the securities at a mutually agreed-upon date (usually not more than seven days from the date of purchase) and price, thereby determining the yield to such Fund during the term of the reverse repurchase agreement.
3. The expected proportion and the maximum proportion of the Fund's NAV that could be subject to reverse repurchase agreements are 30% and 100%. The expected proportions are not limits and the actual percentages may vary over time depending on factors including, but not limited to, market conditions.
4. A Fund may only enter into reverse repurchase agreements with counterparties (typically from OECD countries) in accordance with the requirements of the Central Bank UCITS Regulations where a credit assessment has been undertaken. Where the counterparty is subject to a credit rating by an agency registered and supervised by ESMA, that the rating shall be taken into account to the credit assessment. Where a counterparty is downgraded to A-2 or below (or comparable rating) by such a credit rating agency, a new credit assessment in respect of the counterparty will be undertaken without delay.
5. The Funds will accept the following types of collateral in respect of reverse repurchase agreements
 - (i) government or other public securities;
 - (ii) certificates of deposit issued by Relevant Institutions;
 - (iii) bonds/commercial paper issued by Relevant Institutions or by non-bank issuers where the issue or the issuer are rated A-2 or above from Standard and Poor's (or equivalent);
 - (iv) letters of credit with a residual maturity of three months or less, which are unconditional and irrevocable and which are issued by Relevant Institutions;
 - (v) equity securities traded on a stock exchange in the EEA, Switzerland, Canada, Japan, the United States, Jersey, Guernsey, the Isle of Man, Australia or New Zealand.
6. Collateral in the form of securities (e.g. equities and bonds) will be valued on a daily mark-to-market basis using bid or mid-market prices at the relevant time (or at close of business on the previous business day), obtained from a generally recognised pricing source or reputable dealer. Generally, securities collateral will be valued at bid price because this is the price that would be obtained if the Fund were to sell the securities following a counterparty default. However, mid-market prices may be used where this is the market practice for the relevant transaction. Collateral can typically be called for on a daily basis where the Fund has a net exposure to the counterparty (i.e. if all the transactions were terminated on that day the counterparty would owe the Fund the larger amount), taking into account any thresholds (i.e. levels of exposure below which collateral cannot be required) and after applying any haircuts that will adjust the value of the collateral.
7. While investing in reverse repurchase agreements and in the event of the failure of the counterparty with which cash has been placed, there is the risk that the value of the collateral received may be less than the cash placed out which may be due to factors including inaccurate pricing of the collateral, adverse market movements in the value of the collateral, a deterioration in the credit rating of the issuer of the collateral, or the illiquidity of the market in which the collateral is traded. Locking cash in transactions of significant size or duration, delays in recovering cash placed out, or difficulty in realising collateral may restrict the ability of the relevant Fund to meet redemption requests or fund security purchases. As a Fund may reinvest any cash collateral received from sellers, there is a risk that the value on return of the reinvested cash collateral may decline below the amount owed to those sellers.

8. All assets received in respect of a Fund in the context of efficient portfolio management techniques will be considered as collateral for the purposes of the Central Bank UCITS Regulations. Where there is a title transfer, the collateral received will be held by the Depositary, or its agent. For other types of collateral arrangement, the collateral may be held by a third party depositary which is subject to prudential supervision and which is unrelated to the provider of the collateral.
9. Non-cash collateral received cannot be sold, pledged or re-invested.
10. All the revenues arising from reverse repurchase agreements shall be returned to the relevant Fund following the deduction of any direct and indirect costs and fees arising. Such direct and indirect costs and fees shall include sums payable to the total return payer. Such costs and fees will be at normal commercial rates, if any, and will be borne by the relevant Fund in respect of which the relevant party has been engaged. In principle, the total return payer is not a related party to the Umbrella Fund.
11. The annual report will also inform shareholders of the use the Funds make of reverse repurchase agreements.

Please note the aforementioned disclosures will also be included in the revised STIC prospectus, which has not yet been approved by the CBI and might therefore be subject to change.

Yours faithfully,

Short-Term Investments Company (Global Series) Plc